DFC_MK-7339-008

A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Protocol Number:

In male and female participants with stage IV squamous NSCLC with stable disease, partial
response, or complete response following induction treatment with pembrolizumab combined
with carboplatin and a taxane (paclitaxel or nab-paclitaxel):
Phase III
NCT03976362
Cancer
Lung
Raul Mena, M.D.
Sarah Correa, RN
  • John Wayne Cancer Institute (JWCI)
  • Providence Los Angeles Research Center